Frontlight ResearchEarly access
Taking people in United StatesPhase 2/3
Linsitinib continued in adults with active thyroid eye disease
Tests linsitinib in adults with thyroid eye disease who took part in an earlier study.
Key facts
- Who runs it
- Sling Therapeutics, Inc.
- Where
- Miami and Morgantown, United StatesSee the 2 sites
- Trial code
- Registry title
- Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 75 people, planned
- Started
- 11 Oct 2023
- Planned end
- Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- linsitinib
- Record updated
- 25 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (< 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301
- Subject has not received any treatment for TED since Week 24 of VGN-TED-301
- Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] <50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial
- Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study
Who cannot take part
- The exclusion criteria of protocol VGN-TED-301 also apply to this extension study
This trial is currently available in United States.
- Bascom Palmer Eye InstituteMiami, United StatesContact: Jennifer GomezTaking people
- West Virginia University Eye InstituteMorgantown, United StatesContact: Athena EcholsTaking people
About the trial
What the trial wants to find out
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
The 2 groups in the trial
- Low DoseExisting treatment, for comparison
Active Arm Low Dose Linsitinib
Treatment: linsitinib
- High DoseExisting treatment, for comparison
Active Arm High Dose Linsitinib
Treatment: linsitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- Plain-language title
- Linsitinib continued in adults with active thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
- Record updated
- 25 February 2025